Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus

被引:8
作者
Archer, VR
Mulholland, PJ
Stocken, DD
Darnton, SJ
Ferry, DR
机构
[1] Birmingham Heartlands Hosp, Dept Thorac Surg, Birmingham B9 5SS, W Midlands, England
[2] Univ Birmingham, Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[3] Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TH, W Midlands, England
关键词
adenocarcinoma; antineoplastic agents; cisplatin; combined modality therapy; oesophageal neoplasms; oesophagectomy;
D O I
10.1007/s001740170068
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adenocarcinoma of the oesophagus is a systemic disease at presentation in the majority of patients. This article analyses the impact of preoperative chemotherapy on a cohort of 68 patients. From 1990 to 1996, 68 patients with potentially operable adenocarcinoma of the oesophagus were entered into three sequential Phase II trials of neoadjuvant chemotherapy with cisplatin/mitomycin C/ifosfamide, cisplatin/5-fluorouracil (5-FU) and mitomycin C/cisplatin/5-FU. Twenty-four (35%) patients had a radiological (4 complete; 20 partial) response to chemotherapy, and 52 (76%) went on to have the primary tumour resected. There was only one pathological complete responder. The overall median survival was 13 months (95% confidence interval (CI) 9-16). Survival for the 28 N-0 patients was 34 months (95% CI 14-60). The pattern of failure for resected patients was predominantly systemic (16/17). These results indicate that neoadjuvant chemotherapy followed by surgery for adenocarcinoma of the oesophagus achieves excellent local control. The dominance, however, of distant recurrence after surgery underlines the fact that, in the majority of patients, the only hope of improving results in the future is to develop better systemic therapies.
引用
收藏
页码:164 / 169
页数:6
相关论文
共 33 条
[1]  
AJANI JA, 1994, SEMIN ONCOL, V21, P474
[2]   Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus [J].
Ajani, JA .
CHEST, 1998, 113 (01) :112S-119S
[3]   INTENSIVE PREOPERATIVE CHEMOTHERAPY WITH COLONY-STIMULATING FACTOR FOR RESECTABLE ADENOCARCINOMA OF THE ESOPHAGUS OR GASTROESOPHAGEAL JUNCTION [J].
AJANI, JA ;
ROTH, JA ;
RYAN, MB ;
PUTNAM, JB ;
PAZDUR, R ;
LEVIN, B ;
GUTTERMAN, JU ;
MCMURTREY, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :22-28
[4]   EVALUATION OF PREOPERATIVE AND POSTOPERATIVE CHEMOTHERAPY FOR RESECTABLE ADENOCARCINOMA OF THE ESOPHAGUS OR GASTROESOPHAGEAL JUNCTION [J].
AJANI, JA ;
ROTH, JA ;
RYAN, B ;
MCMURTREY, M ;
RICH, TA ;
JACKSON, DE ;
ABBRUZZESE, JL ;
LEVIN, B ;
DECARO, L ;
MOUNTAIN, C .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1231-1238
[5]   RADICAL LYMPH-NODE DISSECTION FOR CANCER OF THE THORACIC ESOPHAGUS [J].
AKIYAMA, H ;
TSURUMARU, M ;
UDAGAWA, H ;
KAJIYAMA, Y .
ANNALS OF SURGERY, 1994, 220 (03) :364-373
[6]   Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagus [J].
Allen, SM ;
Duffy, JP ;
Darnton, SJ ;
Matthews, HR ;
Cullen, MH .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (05) :496-498
[7]   Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma [J].
Bates, BA ;
Detterbeck, FC ;
Bernard, SA ;
Qaqish, BF ;
Tepper, JE .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :156-163
[8]   RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
BLOT, WJ ;
DEVESA, SS ;
KNELLER, RW ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1287-1289
[9]   CONTINUING CLIMB IN RATES OF ESOPHAGEAL ADENOCARCINOMA - AN UPDATE [J].
BLOT, WJ ;
DEVESA, SS ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (11) :1320-1320
[10]   What is the optimal distal resection margin for esophageal carcinoma? [J].
Casson, AG ;
Darnton, SJ ;
Subramanian, S ;
Hiller, L .
ANNALS OF THORACIC SURGERY, 2000, 69 (01) :205-209